Commercial-stage biotechnology company Adaptive Biotechnologies Corporation (Nasdaq:ADPT) and oncology testing services provider NeoGenomics Inc (Nasdaq:NEO) on Tuesday announced a strategic collaboration to expand access to minimal residual disease (MRD) monitoring for patients with certain blood cancers.
This partnership integrates Adaptive's clonoSEQ MRD test with NeoGenomics' COMPASS and CHART assessment services.
clonoSEQ, an FDA-cleared in vitro diagnostic (IVD) test, detects MRD in lymphoid cancers. COMPASS and CHART offer comprehensive and personalised assessment services for complex blood cancers.
The collaboration will enable clinicians to provide patients with personalised treatment strategies based on advanced MRD monitoring and real-time insights into disease progression.
Initially, the partnership will focus on patients with multiple myeloma, B-cell acute lymphoblastic leukaemia, chronic lymphocytic leukaemia and diffuse large B-cell lymphoma.
clonoSEQ testing will continue to be performed by Adaptive Biotechnologies' CLIA-certified laboratory.
The companies expect to launch cross-promotional efforts later this year.
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review